Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mirum Pharmaceuticals Inc MIRM

Healthcare Biotechnology
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.


NDAQ:MIRM - Post by User

Mirum Pharmaceuticals Inc
<< Previous
 Bullboard Posts
User Avatar Image
(250)
•••
Post by whytestockson Jun 17, 2024 4:30pm
34 Views
Post# 36092854

Outperform Recommendation Issued On MIRM By Evercore ISI

Outperform Recommendation Issued On MIRM By Evercore ISI
Just In: $MIRM Outperform Recommendation Issued On MIRM By Evercore ISI2024-06-17 16:15:02 ET Evercore ISI analyst issues OUTPERFORM recommendation for MIRM on June 17, 2024 03:27PM ET. The previous analyst recommendation was Outperform. MIRM was trading at $32.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...MIRM - Outperform Recommendation Issued On MIRM By Evercore ISI

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities